Engineering programmable CAR and antigen pairing via drug-gated light activation.

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell immunotherapy shows promise but faces challenges in solid tumors, including antigen escape and tumor heterogeneity.
• Current CAR T-cell therapies struggle with specificity and off-tumor toxicity, limiting their application in treating solid malignancies.

Purpose of the Study:

• To engineer a novel programmable CAR T-cell system (DGLA-sPAT) to overcome limitations of current CAR T-cell therapies in solid tumors.
• To enhance spatial control and safety of CAR T-cell activity using a drug-gated light-activation approach (DGLA) and synNotch-mediated programmable antigen-targeting CAR (sPAT).

Main Methods:

• Development of a high-affinity R-phycoerythrin (PE)-binding monobody for PE-programmable CAR construction.
• Implementation of a drug-gated light-activation approach (DGLA) to spatially confine CAR T-cell function.
• Integration of DGLA with synNotch-mediated programmable antigen-targeting CAR (sPAT) to create the DGLA-sPAT system for programmable CAR-antigen pairing.

Main Results:

• The DGLA-sPAT system successfully induced clinically validated antigens on tumor cells, acting as 'training centers' to recruit and activate CAR T cells.
• Demonstrated potent tumor suppression in vivo with localized T-cell activation and minimal off-tumor toxicity.
• The system enabled elimination of entire tumor populations by targeting broadly expressed tumor antigens.

Conclusions:

• The DGLA-sPAT system offers a modular and spatially controlled framework for CAR T-cell therapy in solid tumors.
• This approach effectively addresses challenges of antigen escape and tumor heterogeneity while significantly improving safety profiles.
• DGLA-sPAT represents a promising advancement for enhancing the efficacy and safety of CAR T-cell immunotherapy against solid tumors.